Artificial Intelligence Can Speed Drug Development: Audio Interview

Editor’s Note: In the September 4, 2024 issue of the Jewish Community Voice of Southern New Jersey, Steve Lubetkin’s CompuSchmooze column discusses the use of artificial intelligence (AI) tools in pharmaceutical research. The column is based on this interview with drug researcher Christian Olsen.

It typically takes ten years and $2.5 billion to bring a new drug to market – but now, scientists are using new technology (including AI) to shorten the drug discovery funnel and reduce the costs of drug therapy research.

What does this mean for faster and better treatments?

Christian Olsen is associate vice president and a Business Segment Lead at Dotmatics. Previously, he was a Solutions Architect for the Geneious Biologics Antibody Discovery Platform. His background includes infectious disease and public health, bioinformatics, drug target selection, and drug resistance surveillance.

Boston-based Dotmatics (dotmatics.com) develops analytical platforms for biologic and drug discovery and believes adding artificial intelligence to its data analysis platforms will speed up drug development dramatically.

In this video excerpt, Olsen explains how AI can speed the sequencing of DNA and RNA, essential components of new drug combination experiments.

You can listen to our interview with Olsen in the player below.